Company Encyclopedia
View More
name
MEDLANDER
688273.SH
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation product, and sports rehabilitation products, as well as consumables products, such as vaginal electrodes, rectal electrodes, vaginal probes, etc. The company also provides pelvic floor muscle rehabilitation, biological feedback and stimulation systems, biological stimulation feedback device, consumables/accessories, and ultrasonic uterine involution instruments, as well as PI-ONE, a pelvic floor diagnosis and treatment system.
893.67 B
688273.SHMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking23/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.58%B
    • Profit Margin23.19%A
    • Gross Margin70.02%A
  • Growth ScoreB
    • Revenue YoY14.93%B
    • Net Profit YoY0.35%C
    • Total Assets YoY1.75%C
    • Net Assets YoY3.51%C
  • Cash ScoreB
    • Cash Flow Margin431.31%C
    • OCF YoY14.93%B
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreA
    • Gearing Ratio9.52%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MEDLANDER: Plans to distribute nearly 30 million in dividends for the first three quarters and change its registered address

    MEDLANDER announced that the company will review the profit distribution plan at the third extraordinary general meeting of shareholders in 2025, proposing to distribute a cash dividend of 3 yuan for every 10 shares, totaling 29.3424 million yuan. At the same time, the company plans to change its registered address to No. 1 Hualin Road, Jiangning District, Nanjing, and revise the "Articles of Association."

    Zhitong·
    SH
    688273
    -4.51%
    Zhitong·
    SH
    688273
    -4.51%

    MEDLANDER released its performance for the first three quarters, with a net profit attributable to the parent company of 95.9987 million yuan, a year-on-year decrease of 0.07%

    MEDLANDER released its third-quarter report for 2025, with revenue of 344 million yuan in the first three quarters, a year-on-year increase of 4.01%; net profit attributable to shareholders of 95.9987 million yuan, a year-on-year decrease of 0.07%; net profit excluding non-recurring gains and losses of 79.8 million yuan, a year-on-year decrease of 9.74%; basic earnings per share of 0.9813 yuan. The company plans to distribute a cash dividend of 3.00 yuan (including tax) for every 10 shares to all shareholders

    Zhitong·
    SH
    688273
    -4.51%
    Zhitong·
    SH
    688273
    -4.51%

    MEDLANDER plans to distribute 29.3424 million yuan in cash in the first three quarters of 2025, with no bonus shares or stock dividends

    MEDLANDER announced that it achieved a net profit of 95.9987 million yuan in the first three quarters of 2025 and plans to distribute a cash dividend of 3 yuan for every 10 shares to all shareholders, totaling a cash dividend of 29.3424 million yuan. The company will not convert reserves into share capital or issue bonus shares, with a total of 97.8079 million shares participating in the dividend. This plan needs to be submitted for review at the third extraordinary general meeting of shareholders in 2025

    Zhitong·
    SH
    688273
    -4.51%
    Zhitong·
    SH
    688273
    -4.51%

    Multiple A-share companies reveal progress and product updates in brain-computer interface technology

    In a recent earnings briefing, several A-share listed companies, including Xiangyu Medical, MEDLANDER, BIOTEST BIOTECH, and ZKTECO, disclosed the latest developments in brain-computer interface technology. Some companies expect to achieve revenue within the year, launch new products, and seize development opportunities through investment layouts. In the second half of the year, relevant companies will accelerate investment and product implementation, and local policies will also support commercialization, driving the brain-computer interface industry into a new phase

    Zhitong·
    SH
    688273
    -4.51%
    SH
    688767
    -3.77%
    SZ
    301330
    -0.48%
    Zhitong·
    SH
    688273
    -4.51%
    SH
    688767
    -3.77%
    SZ
    301330
    -0.48%

    MEDLANDER: Net profit for the first half of the year was 63.9201 million yuan, a year-on-year decrease of 11.96%

    On the evening of August 26, MEDLANDER disclosed its 2025 semi-annual report, achieving operating revenue of 241 million yuan in the first half of the year, a year-on-year increase of 5.62%; net profit attributable to the parent company was 63.9201 million yuan, a year-on-year decrease of 11.96%; basic earnings per share were 0.6532 yuan

    Zhitong·
    SH
    688273
    -4.51%
    Zhitong·
    SH
    688273
    -4.51%
    © 2025 Longbridge｜Disclaimer